Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 10.11M | $7.0M | 3.64% | +2.95M | 2026-06-30 |
| ANTIPODES PARTNERS Ltd | 10.10M | $7.0M | 3.64% | +4.38M | 2026-06-30 |
| Alyeska Investment Group, L.P. | 6.02M | $4.0M | 2.17% | -- | 2026-06-30 |
| BlackRock, Inc. | 4.84M | $3.0M | 1.74% | -7.48M | 2026-06-30 |
| GREAT POINT PARTNERS LLC | 3.75M | $2.0M | 1.35% | -- | 2026-06-30 |
| UBS Group AG | 2.84M | $2.0M | 1.02% | +61.4K | 2026-06-30 |
| AQR CAPITAL MANAGEMENT LLC | 2.60M | $2.0M | 0.93% | +672.4K | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.19M | $1.0M | 0.79% | -1.47M | 2026-06-30 |
| MILLENNIUM MANAGEMENT LLC | 1.91M | $1.0M | 0.69% | +1.80M | 2026-06-30 |
| CITADEL ADVISORS LLC | 1.87M | $1.0M | 0.67% | +1.47M | 2026-06-30 |
